Patty Bunch

508 total citations
6 papers, 422 citations indexed

About

Patty Bunch is a scholar working on Radiology, Nuclear Medicine and Imaging, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Patty Bunch has authored 6 papers receiving a total of 422 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Radiology, Nuclear Medicine and Imaging, 2 papers in Pathology and Forensic Medicine and 2 papers in Oncology. Recurrent topics in Patty Bunch's work include Radiopharmaceutical Chemistry and Applications (3 papers), Neuroendocrine Tumor Research Advances (2 papers) and Peptidase Inhibition and Analysis (2 papers). Patty Bunch is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (3 papers), Neuroendocrine Tumor Research Advances (2 papers) and Peptidase Inhibition and Analysis (2 papers). Patty Bunch collaborates with scholars based in United States and France. Patty Bunch's co-authors include Julien Torgue, Ruby F. Meredith, Sui Shen, Ronald D. Alvarez, J. Michael Straughn, Antonio J Grillo-López, John Gutheil, Albert F. LoBuglio, M. R. Moore and Lori Kunkel and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Nuclear Medicine and American Journal of Clinical Oncology.

In The Last Decade

Patty Bunch

6 papers receiving 415 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Patty Bunch United States 4 290 139 83 77 55 6 422
Frank Heinzelmann Germany 14 111 0.4× 156 1.1× 110 1.3× 79 1.0× 35 0.6× 37 443
Ellen Kornmehl United States 4 224 0.8× 103 0.7× 66 0.8× 40 0.5× 147 2.7× 6 377
JF Eary United States 7 288 1.0× 65 0.5× 141 1.7× 97 1.3× 195 3.5× 12 434
D Snook United Kingdom 11 344 1.2× 91 0.7× 107 1.3× 12 0.2× 38 0.7× 13 453
Dave Yamauchi United States 16 433 1.5× 158 1.1× 320 3.9× 29 0.4× 192 3.5× 35 713
C. Stucchi Italy 13 81 0.3× 127 0.9× 84 1.0× 42 0.5× 19 0.3× 27 420
H. Ortíz United States 7 99 0.3× 238 1.7× 215 2.6× 89 1.2× 48 0.9× 14 609
Ranjit K. Goudar United States 9 155 0.5× 412 3.0× 125 1.5× 34 0.4× 59 1.1× 16 676
M Harrison United States 7 224 0.8× 83 0.6× 199 2.4× 92 1.2× 36 0.7× 9 488
Mark Becker United States 7 330 1.1× 334 2.4× 172 2.1× 20 0.3× 199 3.6× 10 731

Countries citing papers authored by Patty Bunch

Since Specialization
Citations

This map shows the geographic impact of Patty Bunch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patty Bunch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patty Bunch more than expected).

Fields of papers citing papers by Patty Bunch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patty Bunch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patty Bunch. The network helps show where Patty Bunch may publish in the future.

Co-authorship network of co-authors of Patty Bunch

This figure shows the co-authorship network connecting the top 25 collaborators of Patty Bunch. A scholar is included among the top collaborators of Patty Bunch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patty Bunch. Patty Bunch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

6 of 6 papers shown
1.
Meredith, Ruby F., Julien Torgue, Tania A. Rozgaja, et al.. (2016). Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab. American Journal of Clinical Oncology. 41(7). 716–721. 85 indexed citations
2.
Meredith, Ruby F., Julien Torgue, Sui Shen, et al.. (2014). Dose Escalation and Dosimetry of First-in-Human α Radioimmunotherapy with 212Pb-TCMC-Trastuzumab. Journal of Nuclear Medicine. 55(10). 1636–1642. 104 indexed citations
3.
Meredith, Ruby F., Julien Torgue, Michael Azure, et al.. (2013). Pharmacokinetics and Imaging of 212 Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients. Cancer Biotherapy and Radiopharmaceuticals. 29(1). 12–17. 107 indexed citations
4.
Bhoola, Snehal M., Jacob M. Estes, Charles A. Leath, et al.. (2004). Weekly topotecan is well tolerated in the third-line or later treatment of patients with epithelial ovarian carcinoma (EOC) and may prolong time to disease progression. Journal of Clinical Oncology. 22(14_suppl). 5067–5067. 1 indexed citations
5.
Bhoola, Snehal M., Jacob M. Estes, Charles A. Leath, et al.. (2004). Weekly topotecan is well tolerated in the third-line or later treatment of patients with epithelial ovarian carcinoma (EOC) and may prolong time to disease progression. Journal of Clinical Oncology. 22(14_suppl). 5067–5067. 2 indexed citations
6.
Saleh, Mansoor N., John Gutheil, M. R. Moore, et al.. (2000). A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia.. PubMed. 27(6 Suppl 12). 99–103. 123 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026